QTX125

Quimatryx Ltd has designed a best in class HDAC6 selective inhibitor, QTX125, with the aim of reducing the side-effects of the treatment and beating the therapeutic activity of other HDAC inhibitors.

In an in vivo xenograft assay with mantle cell lymphoma cell lines, QTX125 showed a spectacular tumour regression effect without toxicity. In addition, QTX125 does not present genotoxicity in rats and has successfully completed the in vitro hERG cardiotoxicity study.

QTX125 compound and its clinical indications are fully protected by the corresponding patents: WO2011/039353, US8685992, EP2483242, ZL201080052814, MX314175, JP5746185, RU2549885